Biblio
Age is a prognostic factor for the overall survival of multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2019.
Autologous Stem Cell Transplantation for Multiple Myeloma: Growth Factor Matters. Biol Blood Marrow Transplant. 2019.
Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM. Blood Adv. 2020;4(19):4834-4837.
Black multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to whites: a propensity-score matched analysis. Am J Hematol. 2021.
Myeloablative Fractionated Busulfan with Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical Trial. Transplant Cell Ther. 2021.
Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. J Clin Oncol. 2021:JCO2002608.
HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM-CELL TRANSPLANT FOR RELAPSED OR REFRACTORY PRIMARY MEDIASTINAL B-CELL LYMPHOMA. Transplant Cell Ther. 2023.
Impact of gender on outcomes of patients with multiple myeloma undergoing autologous Haematopoietic stem cell transplant. Br J Haematol. 2023.
Outcomes of Autologous Stem Cell Transplant in Patients with Ultra High-Risk Multiple Myeloma. Transplant Cell Ther. 2023.
Outcomes of young adults (aged ≤ 40 years) with newly diagnosed multiple myeloma after up-front autologous stem cell transplant. Br J Haematol. 2023.
Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation. Br J Haematol. 2024.
Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation. Blood Cancer J. 2024;14(1):82.